| Securities at fair value through other comprehensive income (FVOCI) |
Securities at fair value through other comprehensive income (FVOCI) The accounting policy on financial assets and liabilities is presented in Note 2c IV. | | | | | | | | | | | | | | | | | | | | | | | | | 12/31/2025 | | 12/31/2024 | | Gross book value | Fair value adjustment | Fair value | | Gross book value | Fair value adjustment | Fair value | | Government securities | 122,487 | | (1,597) | | 120,890 | | | 102,483 | | (3,610) | | 98,873 | | | Brazil | 83,366 | | (1,603) | | 81,763 | | | 67,990 | | (3,613) | | 64,377 | | | Latin America | 25,173 | | (30) | | 25,143 | | | 21,421 | | 49 | | 21,470 | | | Abroad | 13,948 | | 36 | | 13,984 | | | 13,072 | | (46) | | 13,026 | | | Corporate securities | 11,381 | | (578) | | 10,803 | | | 7,219 | | (355) | | 6,864 | | | Rural product note | - | | - | | - | | | 127 | | (1) | | 126 | | | Bank deposit certificates | 168 | | (1) | | 167 | | | 82 | | 1 | | 83 | | | Real estate receivables certificates | 221 | | 1 | | 222 | | | 60 | | (3) | | 57 | | | Debentures | 4,582 | | (169) | | 4,413 | | | 1,708 | | (210) | | 1,498 | | | Eurobonds and other | 6,281 | | (410) | | 5,871 | | | 4,957 | | (145) | | 4,812 | | | Financial bills | 5 | | - | | 5 | | | 51 | | 2 | | 53 | | | Other | 124 | | 1 | | 125 | | | 234 | | 1 | | 235 | | | Total | 133,868 | | (2,175) | | 131,693 | | | 109,702 | | (3,965) | | 105,737 | | | Shares (designated at FVOCI) | 1,840 | | (1,060) | | 780 | | | 1,762 | | (1,196) | | 566 | | | Total | 135,708 | | (3,235) | | 132,473 | | | 111,464 | | (5,161) | | 106,303 | | | Expected credit loss (Income) | (480) | | | | | (257) | | | | | Fair value adjustment (OCI) | (2,755) | | | | | (4,904) | | | | | Fair value | 132,473 | | | | | 106,303 | | | |
The Securities pledged in guarantee of funding transactions with financial institutions and customers and post-employment benefits (Note 26b), are: a) Government securities - Brazil R$ 29,581 (R$ 33,971 at 12/31/2024), b) Government securities - Latin America R$ 3,519 (R$ 3,050 at 12/31/2024), c) Government securities - Abroad R$ 1,113 (R$ 0 at 12/31/2024) and d) Corporate securities R$ 3,125 (R$ 986 at 12/31/2024), totaling R$ 37,338 (R$ 38,007 at 12/31/2024). Regarding the shares designated to FVOCI, there was no receipt of dividends and sale of shares in the period. Securities at FVOCI, by maturity: | | | | | | | | | | | | | | | | | | | 12/31/2025 | | 12/31/2024 | | Gross book value | Fair value | | Gross book value | Fair value | | Current | 43,812 | | 42,729 | | | 41,123 | | 39,877 | | | Non-stated maturity | 1,840 | | 781 | | | 1,762 | | 566 | | | Up to one year | 41,972 | | 41,948 | | | 39,361 | | 39,311 | | | Non-current | 91,896 | | 89,744 | | | 70,341 | | 66,426 | | | From one to five years | 66,032 | | 66,206 | | | 49,121 | | 47,809 | | | From five to ten years | 15,687 | | 15,154 | | | 11,201 | | 10,803 | | | After ten years | 10,177 | | 8,384 | | | 10,019 | | 7,814 | | | Total | 135,708 | | 132,473 | | | 111,464 | | 106,303 | |
Reconciliation of expected credit loss for securities at FVOCI, except for shares designated at FVOCI, segregated by stages: | | | | | | | | | | | | | | | | | | | | | | | | | | | | Stage 1 | Balance at 12/31/2024 | Transfer to stage 2 | Transfer to stage 3 | Cure from stage 2 | Cure from stage 3 | (Increase) / Reversal | Write-off | Balance at 12/31/2025 | | Government securities | (43) | | — | | — | | — | | — | | 40 | | — | | (3) | | | Corporate securities | (73) | | — | | 14 | | (14) | | — | | 58 | | — | | (15) | | | Total | (116) | | — | | 14 | | (14) | | — | | 98 | | — | | (18) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Stage 2 | Balance at 12/31/2024 | Cure to stage 1 | Transfer to stage 3 | Transfer from stage 1 | Cure from stage 3 | (Increase) / Reversal | Write-off | Balance at 12/31/2025 | | Corporate securities | (127) | | 14 | | 113 | | - | | - | | - | | - | | - | | | Total | (127) | | 14 | | 113 | | - | | - | | - | | - | | - | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Stage 3 | Balance at 12/31/2024 | Cure to stage 1 | Cure to stage 2 | Transfer from stage 1 | Transfer from stage 2 | (Increase) / Reversal | Write-off | Balance at 12/31/2025 | | Corporate securities | (14) | | - | | - | | (14) | | (113) | | (321) | | - | | (462) | | | Total | (14) | | - | | - | | (14) | | (113) | | (321) | | - | | (462) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Stage 1 | Balance at 12/31/2023 | Transfer to stage 2 | Transfer to stage 3 | Cure from stage 2 | Cure from stage 3 | (Increase) / Reversal | Write-off | Balance at 12/31/2024 | | Government securities | (38) | | - | | - | | - | | - | | (5) | | - | | (43) | | | Corporate securities | (79) | | 55 | | — | | (21) | | — | | (28) | | — | | (73) | | | Total | (117) | | 55 | | — | | (21) | | — | | (33) | | — | | (116) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Stage 2 | Balance at 12/31/2023 | Cure to stage 1 | Transfer to stage 3 | Transfer from stage 1 | Cure from stage 3 | (Increase) / Reversal | Write-off | Balance at 12/31/2024 | | Corporate securities | (24) | | 21 | | - | | (55) | | - | | (69) | | - | | (127) | | | Total | (24) | | 21 | | - | | (55) | | - | | (69) | | - | | (127) | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Stage 3 | Balance at 12/31/2023 | Cure to stage 1 | Cure to stage 2 | Transfer from stage 1 | Transfer from stage 2 | (Increase) / Reversal | Write-off | Balance at 12/31/2024 | | Corporate securities | (26) | | - | | - | | - | | - | | 12 | | - | | (14) | | | Total | (26) | | - | | - | | - | | - | | 12 | | - | | (14) | |
|